

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma (ID: i768)
Tweetorial #1 References

Tweet 4

Nadal R, Apolo AB. Overview of current and future adjuvant therapy for muscle-invasive urothelial carcinoma. *Curr. Treat. Options in Oncol.* 2018;19:36. <https://doi.org/10.1007/s11864-018-0551-z>

Massari F, Santoni M, di Nunno V, et al. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. *Cancer Treatment Reviews.* 2018;68:80-85.
<https://doi.org/10.1016/j.ctrv.2018.06.002>

Tweet 5

Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology.* 2007;69:1. <https://doi.org/10.1016/j.urology.2006.10.041>

Pederzoli F, Bandini M, Briganti A, et al. Incremental utility of adjuvant chemotherapy in muscle-invasive bladder cancer: quantifying the relapse risk associated with therapeutic effect. *European Urology.* 2019;76:4. <https://doi.org/10.1016/j.eururo.2019.06.032>

Tweet 8

Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology.* 2007;69:1. <https://doi.org/10.1016/j.urology.2006.10.041>

Tweet 9

Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology.* 2007;69:1. <https://doi.org/10.1016/j.urology.2006.10.041>

Tweet 13

Bellmunt J, Hussain PM, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology.* 2021;22:4. [https://doi.org/10.1016/S1470-2045\(21\)00004-8](https://doi.org/10.1016/S1470-2045(21)00004-8)

Tweet 14

Wallis CJD. ASCO GU 2021: First results from the phase 3 checkmate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma. Presented at 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 11th-February 13th, 2021; Virtual.

Tweet 15

Kadow B. ASCO GU 2019: Pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma - AMBASSADOR versus observation. Presented at 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14-16, 2019; San Francisco, CA.

Pal S K, Daneshmand S, Matin SF, et al. PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring *FGFR3* alterations. *Journal of Clinical Oncology*. 2020;38:6.
10.1200/JCO.2020.38.6_suppl.TPS600 *Journal of Clinical Oncology* 38, no. 6_suppl

Glossary

%, percentage
b/f, before
CI, confidence interval
DFS, disease-free survival
Dz, Disease
ECOG, Eastern Cooperative Oncology Group
FGFR3, fibroblast growth factor receptor 3
FGFR1-3, fibroblast growth factor receptor 1
HR, hazard ratio
ICI, intracavernosal injection
M0, non-metastasized stage
MIUC, muscle-invasive urothelial carcinoma
PBO, placebo
PD-1, programmed death-1
PD-L1, Programmed death-ligand 1
pN+, tumor-specific stages
Pt, patient
pT3, urothelial carcinoma subtype
pT3-pT4a, problematic issue in Tn stage
RCT, randomized controlled trial
RT, radiation therapy
T3, cancer stage
T4, cancer stage
TRAE, treatment-related adverse event
Tx, treatment
UC, urologic cancer
UTUC, upper tract urothelial carcinoma
ypN+, tumor-specific stages
ypT2-4a, tumor-specific stages